Turkey unveils deal for 50 mn Sputnik V doses

coronavirus
Credit: Pixabay/CC0 Public Domain

Turkey announced on Wednesday it has signed a deal for the delivery of 50 million doses of Russia's Sputnik V coronavirus vaccine.

Health Minister Fahrettin Koca said the first deliveries will arrive in May as Turkey tries to speed up the innoculation effort.

The nation of 84 million has delivered one shot to more than 13.5 million people and the full two doses to nearly nine million since launching its vaccination drive with China's CoronaVac jab in mid-January.

Koca said Turkey was also extending the time between the first and second shots of BionTech/Pfizer from the current four weeks to six-eight.

Turkey has so far secured only 4.5 million BionTech/Pfizer doses and is experiencing delays in the of a promised 100 million shots from China.

"The vaccine supply is getting more difficult over the coming two months, but we expect it to become more abundant thereafter," Koca said.

Turkey goes into a 17-day lockdown starting on Thursday to combat a sharp spike of COVID-19 infections and deaths.

The restrictions are harsher than during two previous waves last year.

People will be barred from going outdoors without a valid reason and are being limited to discourage public gatherings.

The third wave has also been deadlier than the previous two.

Turkey has been reporting around 350 deaths daily for the past week. Official numbers approached 60,000 a day earlier this month before slipping down to 40,000—still the highest in Europe.

A total of more than 39,000 deaths and 4.7 million infections have been recorded since the pandemic began.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: Turkey unveils deal for 50 mn Sputnik V doses (2021, April 28) retrieved 25 October 2021 from https://medicalxpress.com/news/2021-04-turkey-unveils-mn-sputnik-doses.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors